ConductScience.org, home

Comparison · NCT01284348-9f826496

Sotatercept 15 mg vs Sotatercept 30 mg: Number of Participants Who Experienced a Hematopoietic Response

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Sotatercept 15 mg vs Sotatercept 30 mg: Number of Participants Who Experienced a Hematopoietic Response. Trial comparisons, record NCT01284348-9f826496. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01284348-9f826496

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1430.04010.399wilson
Risk in group 20.1820.05140.477wilson
Risk difference, group 1 minus group 2-0.039-0.3520.249newcombe hybrid score
Risk ratio, group 1 over group 20.7860.1314.72log
Odds ratio, group 1 over group 20.750.08816.39log
Number needed to treat, for one fewer participant with the outcome on Sotatercept 15 mg than on Sotatercept 30 mg25.7from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Sotatercept 15 mgParticipants received sotatercept 15 mg by SC injection once every 42 days, up to four doses.214OG000
Group 2Sotatercept 30 mgParticipants received sotatercept 30 mg by SC injection once every 42 days, up to four doses.211OG001

Outcome

Type
PRIMARY
Title
Number of Participants Who Experienced a Hematopoietic Response
Description
A hematopoietic response was defined as an increase in a participant's hemoglobin (Hgb) of ≥1.0 g/dL above the study baseline value for 4 consecutive weeks, in the absence of red blood cell transfusion and/or erythropoiesis-stimulating agents.
Time frame
Up to Day 28
Population
All participants who received at least 1 dose of study drug

Source ClinicalTrials.gov

Trial

Title
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
NCT number
NCT01284348
Phases
PHASE2
Conditions
Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer, Cancer of Head and Neck, Uterine Cervical Cancer
Interventions
Sotatercept 15 mg, Sotatercept 30 mg
Lead sponsor
Merck Sharp & Dohme LLC
Results first posted
2023-10-31

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01284348-9f826496